Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J P Eder

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1993
Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposideC Wheeler, M Strawderman, L Ayash, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1990
A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patientsJ P Eder, A Elias, T C Shea, et al.
Contributions to Nephrology|January 1, 1991
Erythropoietin gene regulation: from the laboratory to the bedsideM A Goldberg, C C Gaut, L Schapira, et al.
Langmuir : the ACS Journal of Surfaces and Colloids|April 11, 2009
A two-step method to covalently bind biomolecules to group-IV semiconductors: Si(111)/1,2-epoxy-9-decene/esteraseClaire Jeanquartier, Gerburg Schider, Sabine Feichtenhofer, et al.
Archives of Dermatology|June 1, 1988
Malignant melanoma. Treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow supportT C Shea, K H Antman, J P Eder, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2001
Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignanciesD P Ryan, J G Supko, J P Eder, et al.
British Journal of Cancer|June 30, 2005
A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumoursR T Penson, M V Seiden, U A Matulonis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2000
A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancerJ P Eder, P W Kantoff, K Roper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2001
Phase I and pharmacokinetic study of LU79553, a DNA intercalating bisnaphthalimide, in patients with solid malignanciesM A Villalona-Calero, J P Eder, D L Toppmeyer, et al.
Annals of the New York Academy of Sciences|December 13, 1996
Trials of 9-amino-20(S)-camptothecin in BostonJ P Eder, E Rubin, R Stone, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1993
Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposideC Wheeler, M Strawderman, L Ayash, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1990
A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patientsJ P Eder, A Elias, T C Shea, et al.
Contributions to Nephrology|January 1, 1991
Erythropoietin gene regulation: from the laboratory to the bedsideM A Goldberg, C C Gaut, L Schapira, et al.
Langmuir : the ACS Journal of Surfaces and Colloids|April 11, 2009
A two-step method to covalently bind biomolecules to group-IV semiconductors: Si(111)/1,2-epoxy-9-decene/esteraseClaire Jeanquartier, Gerburg Schider, Sabine Feichtenhofer, et al.
Archives of Dermatology|June 1, 1988
Malignant melanoma. Treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow supportT C Shea, K H Antman, J P Eder, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2001
Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignanciesD P Ryan, J G Supko, J P Eder, et al.
British Journal of Cancer|June 30, 2005
A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumoursR T Penson, M V Seiden, U A Matulonis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2000
A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancerJ P Eder, P W Kantoff, K Roper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2001
Phase I and pharmacokinetic study of LU79553, a DNA intercalating bisnaphthalimide, in patients with solid malignanciesM A Villalona-Calero, J P Eder, D L Toppmeyer, et al.
Annals of the New York Academy of Sciences|December 13, 1996
Trials of 9-amino-20(S)-camptothecin in BostonJ P Eder, E Rubin, R Stone, et al.
Pageof 6